参考文献

本書（Anabolics 11th Edition）の内容は、多数の科学研究、臨床試験、医学文献に基づいています。以下はその主要な参考文献です。

テストステロンとアンドロゲン研究

テストステロンの用量反応、酵素誘導、脂質代謝への影響、代謝経路（アロマターゼ化、DHT変換）などに関する研究。

代表的なトピック：

• テストステロン補充療法の用量反応関係
• テストステロンのHDL/LDLコレステロールへの影響
• アロマターゼ阻害とエストロゲン制御
• 5α-還元酵素の組織特異的活性

アナボリックステロイド研究

各化合物の臨床研究：

• オキシメトロン（アナポロン）のエイズ消耗症候群への応用
• ナンドロロンデカン酸エステル（デカ）の臨床試験
• オキサンドロロン（アナバー）の成長障害治療
• フルオキシメステロン（ハロテストチン）の乳がん治療
• 各AASの肝毒性評価
• 性腺機能低下症とホルモン抑制

成長因子とホルモン

• hCG（ヒト絨毛性ゴナドトロピン）の臨床応用
• 成長ホルモン（GH）の補充療法
• GHRH/セルモレリンの研究
• 成長不全症とリポジストロフィー

サポート療法

• コレステロール管理（オメガ3、スタチン、ハーブ）
• 肝臓保護（Liv.52、N-アセチルシステイン）
• 血圧管理
• 心血管系サプリメント

歴史的文献

• 1930年代の初期テストステロン研究
• アナボリックステロイドの基礎的教科書
• 内分泌学の古典的文献

注意事項

これらの参考文献は情報源としての参照用であり、全ての文献が特定の使用法や用量を支持するものではありません。医療的判断には、必ず最新の一次文献と医療専門家の見解を参照してください。

関連ページ

• PCTの参考文献 — PCT関連の文献
• 用語集 — PED関連の略語・用語の解説

詳細参考文献

以下はAnabolics 11th Edition Part III（薬剤プロファイル）で参照されている学術文献の一覧です。

379. Experiences with a new testosterone isobutyrate crystal suspension. Drescher H. Dtsch Med Wochenschr. 1952 Apr 4;77(14):431-2.

380. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. Clin Pharmacol Ther (1976) 20:233-237.

381. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) 1990:69-74.

382. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab (2001) 281:E1172-81.

383. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab (2002) 87:136-43. 384.2-Methyl and 2-hydroxymethylene-androstane derivatives. Ringold HJ et al. J Am Chem Soc 1959;81:427-32.

385. Oxymetholone treatment for the anemia of bone marrow failure. Alexanian R, Nadell J, et al. Blood. 1972; 40:353-6.

386. Les hormones anabolisantes du point de vue experimental. P.A. Desaulles. Helv. Med. Acta 1960:479-

503.

387. Studies on anabolic steroids-8. GC/MS characterization of unusual seco acidic metabolites of oxymetholone in human urine. J Steroid Biochem Mol Bio 42 (1992):229-42.

388. Effects of various 17 alpha alkyl substitutions and structural modifications oof steroids on sulfobromophthalein (BSP) renention in rabbits. Lennon HD et al. Steroids 7 (1966): 157-70.

389. Long-term oxymetholone use in HIV patients not associated with significant hepatotoxicity. Hengge UR et al. Poster presented at the Third International Conference on Nutrition and HIV Infection; April 22-25, 1999; Cannes, France.

390. Effects of an oral androgen on muscle and metabolism in older, community-dwelling men. Schroeder et al.Am J Physiol Endocrinol.Metab. 284:E120- 28.

391. Diezfalusy E. Acta endocrin. (Kbh.) 35 (1960):59.

392. Biosynthesis of Estrogens, Gual C, Morato T, Hayano M, Gut M, and Dorfman R. Endocrinology 71 (1962):920-25.

393. Aromatization of androstenedione and 19-nortestosterone in human placental, liver and adipose tissues (abstract). Nippon Naibunpi Gakkai Zasshi 62 (1986):18-25.

394. Competitive progesterone antagonists: receptor binding and biologic activity of testosterone and 19-nortestosterone derivatives. Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Fertil Steril 1979 May;31(5):552-61.

395. Studies of the biological activity of certain 19-nor steroids in female animals. Pincus G, Chang M, Zarrow M, Hafez E, Merrill A. December 1956.

396. Different Pattern of Metabolism Determine the Relative Anabolic Activity of 19-Norandrogens. J Steroid Biochem Mol Bio 53(1995):255-7.

397. Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha reduced derivatives to the androgen receptor and to other Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha reduced derivatives to the androgen receptor and to other nortestosterone. Toth M, Zakar T. J Steroid Biochem 17 (1982):653-60.

398. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1214-22. Epub 2002 Aug 27.

399. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Crist DM, Peake GT, Stackpole PJ. Clin Exp Pharmacol Physiol 1986 Jul;13(7):513-8.

400. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. Karl E. Friedl et al. J Clin Endocrinol Metab 68: 971, 1989.

401. Influence of nandrolonedecanoate on the pituitary-gonadal axis in males. Bijlsma J, Duursma S, Thijssen J, Huber O. Acta Endocrinol 101 1982:108-12

402. Oxandrolone: A Potent Anabolic Steroid of Novel Chemical Composition. Fox M, Minot AS, and Liddle GW. Journal of Clinical Endocrinology and Metabolism. 1962; Volume 22, Pgs. 921-924.

403. M. Fox et al. J. Clin Endocrinol Metab 22 (1962):921.

404. Published reference of personal communication from Saunders F.J. (April 21, 1961) to author of Methyltestosterone, related steroids, and liver function. Arch Int. Med 116 (1965):289-94.

405. Studies on anabolic steroids. II—Gas chromatographic/mass spectrometric characterization of oxandrolone urinary metabolites in man. Masse R, Bi HG,Ayotte C, Dugal R. Biomed Environ Mass Spectrom. 1989 Jun;18(6):429-38.

406. Methyltestosterone, related steroids, and liver function. DeLorimier, Gordan G, Lowe R. et al. Arch Int. Med 116 (1965):289-94.

407. Effects of Oxandrolone on Plasma Lipoproteins and the Intravenous Fat tolerance in Man. Atherosclerosis 19 (1974):337-46.

408. Oxandrolone and Plasma Triglyceride Reduction: Effect of Triglyceride-Rich Diet and High Density Lipoproteins. Artery 9 (1981):328-41.

409. Plasma and Lipoprotein Lipid Responses to Four Hypolipid Drugs. Lipids 19 (1984):73-79.

410. The effects of oxandrolone on the growth hormone and gonadal axis in boys with constitutional delay of growth and puberty. Malhitra A, Poon E. Et al. Clin Endocrinol (Oxf ) 1993 Apr;38(4):393-8.

411. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

412. Butenandt AK et al. Ber dtsch chem. Ges. 68 (1935):2097.

413. Comparative pharmacokinetics of three doses of percutaneous dihydrotestosterone gel in healthy elderly men—a clinical research center study.Wang C, Iranmanesh A, Berman N et al. J Clin Endocrinol Metab 1998 Aug;83(8):2749-57.

414. Transdermal dihydrotestosterone treatment of ‘andropause’. Ann Med. 1993 Jun;25(3):235-41.

415. Studies on the treatment of idiopathic gynaecomastia with percutaneous dihydrotestosterone. Clin Endocrinol (Oxf ). 1983 Oct;19(4):513-20.

416. Gynecomastia: effect of prolonged treatment with dihydrotestosterone by the percutaneous route Presse Med. 1983 Jan 8;12(1):21-5.

417. Contribution of lymphatically transported testosterone undecanoate to the systemic exposure of testosterone after oral administration of two andriol formulations in conscious lymph duct-cannulated dogs. Shackleford D, Faassen W Aet al. J of Pharm and Exper Ther. 306 (2003):925–933.

418. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

419. A ten-year safety study of the oral androgen testosterone undecanoate. Gooren LJG , J Androl , 1994 , 15 , 212–5.

420. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Mårin P, Holmång S, Jöhnsson L, et al. Int J Obes , 1992 , 16 , 991-7.

421. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F 1976 Clin Pharmacol Ther 20:233-237.

422. Testosterone replacement, cardiovascular system and risk factors in the aging male. Vigna GB, Bergami E. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):69-74.

423. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Marbury T, Hamill E, Bachand R, Sebree T, Smith T. Biopharm Drug Dispos. 2003 Apr;24(3):115-20.

424. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

425. Testosterone replacement, cardiovascular system and risk factors in the aging male. Vigna GB, Bergami E. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):69-74.

426. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

427. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) (1990):69-74.

428. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281 (2001):E1172-81.

429. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Atam Singh, Stanley Hsia, et al. J Clin Endocrinol Metab 87 (2002):136-43.

430. Lyster SC, et al. Acta Endocrin (Kbh) 43 (1963):

399.

431. The biological activity of 7 alpha-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology. 1992 Jun; 130(6):3677-83.

432. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

433. De Visser, J. et al. Acta Endocrin. (Kbh.) 35 (1960):

405.

434. Biosynthesis of Estrogens, Gual C, Morato T, Hayano M, Gut M and Dorfman R. Endocrinology 71 (1962):920-25.

435. Aromatization of androstenedione and 19-nortestosterone in human placental, liver and adipose tissues (abstract). Nippon Naibunpi Gakkai Zasshi 62 (1986):18-25.

436. Competitive progesterone antagonists: receptor binding and biologic activity of testosterone and 19-nortestosterone derivatives. Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Fertil Steril 1979 May;31(5):552-61.

437. Studies of the biological activity of certain 19-nor steroids in female animals. Pincus G, Chang M, Zarrow M, Hafez E, Merrill A. December 1956.

438. Different Pattern of Metabolism Determine the Relative Anabolic Activity of 19-Norandrogens. J Steroid Biochem Mol Bio 53:255-7,1995.

439. Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha reduced derivatives to the androgen receptor and to other androgen-binding proteins: A suggested role of 5alpha-reductive steroid metabolism in the dissociation of “myotropic” and “androgenic” activities of 19- nortestosterone.Toth M, Zakar T. J Steroid Biochem 17 (1982):653-60.

440. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1214-22. Epub 2002 Aug 27.

441. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Crist DM, Peake GT, Stackpole PJ. Clin Exp Pharmacol Physiol 1986 Jul;13(7):513-8.

442. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. Karl E. Friedl et al. J Clin Endocrinol Metab 68: 971, 1989.

443. Influence of nandrolonedecanoate on the pituitary-gonadal axis in males. Bijlsma J,Duursma S,Thijssen J, Huber O.Acta Endocrinol 101 (1982):108- 12.

444. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss. K Mulligan, R Zackin, et al. Arch Intern Med. (2005):165:578-85.

445. Nandrolone decanoate: Pharmacological properties and therapeutic use in osteoporosis. P Geusens. Clinical Rheumatology, 1995, 14, Suppl. 3.

446. Contraceptive efficacy and adverse effects of testosterone enanthate in Thai men. Sukcharoen N, Aribarg A, Kriangsinyos R, Chanprasit Y, Ngeamvijawat J. J Med Assoc Thai 1996 Dec;79(12):767-73.

447. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

448. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) (1990):69-74.

449. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281 (2001):E1172-81.

450. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Atam Singh, Stanley Hsia, et al. J Clin Endocrinol Metab 87 (2002):136-43.

451. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

452. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) (1990):69-74.

453. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281 (2001):E1172-81.

454. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab 87 (2002):136-43.

455. Biological half-lives of [4-14C]testosterone and some of its esters after injection into the rat. James KC, Nicholls PJ, and Roberts M.J, Pharm. Pharmacol 21 (1969):24-27.

456. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

457. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) 1990:69-74.

458. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281 (2001):E1172-81.

459. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab 87 (2002):136-43.

460. Vischer E, Meystre C, Wettstein A. Helv Chim Acta 38 (1955):1502.

461. Never Enough / Steroids in Sports: Experiment turns epidemic. Robert Dvorchak. Pittsburgh Post-Gazette January 14, 2005.

462. Comments from Dr. John Ziegler. Strength & Heath Magazine, 1967.

463. Officials bungled steroid regulation from the start. Robert Dvorchak, Pittsburgh Post-Gazette October 3, 2005.

464. Anabolic-androgenic steroid interaction with rat androgen receptor in vivo and in vitro: a comparative study. Feldkoren BI, Andersson S. J Steroid Biochem Mol Biol. 2005 Apr;94(5):481-7. Epub 2005 Mar 17.

465. Kruskemper, H L, Anabolic Steroids, Academic Press, New York, 1968.

466. Relative imporance of 5alpha reduction for the androgenic and LH-inhibiting activities of delta-4-3-ketosteroids. Steroids 29 (1997):331-48.

467. Anabolic steroids in clinical medicine. Liddle GW, Burke jr. H A Helvetica Medica Acta, 5/6 1960:504-13.

468. Effect of anabolic steroid (metandienon) on plasma LH-FSH, and testosterone and on the response to intravenous administration of LRH. Holma P, Adlercreutz. Acta Endocrinol (Copenh) 1976 Deca;83(4):856-64.

469. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

470. Inhibition of the estrogenic activity of methylandrostenediol following administration of aminopterin . Boll Soc Ital Biol Sper. 31(9-10) Sep-Oct (1955):1280-4.

471. Overbeek G A, J. de Visser: Acta endocrin. (Kbh.) 24 (1957):209.

472. Biosynthesis of Estrogens, Gual C, Morato T, Hayano M, Gut M and Dorfman R. Endocrinology 71 (1962):920-25.

473. Aromatization of androstenedione and 19-nortestosterone in human placental, liver and adipose tissues (abstract). Nippon Naibunpi Gakkai Zasshi 62 (1986):18-25.

474. Competitive progesterone antagonists: receptor binding and biologic activity of testosterone and 19-nortestosterone derivatives. Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Fertil Steril 31(5) May (1979):552-61.

475. Studies of the biological activity of certain 19-nor steroids in female animals. Pincus G, Chang M, Zarrow M, Hafez E, Merrill A. December 1956.

476. Different Pattern of Metabolism Determine the Relative Anabolic Activity of 19-Norandrogens. J Steroid Biochem Mol Bio 53 (1995):255-7.

477. Relative binding affinities of testosterone, 19-nortestosterone and the 5-alpha reduced derivatives to the androgen receptor and to other androgenRelative binding affinities of testosterone, 19-nortestosterone and the 5-alpha reduced derivatives to the androgen receptor and to other androgen nortestosterone. Toth M, Zakar T. J Steroid Biochem 17 (1982):653-60.

478. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Am J Physiol Endocrinol Metab. 283(6) Dec (2002):E1214-22. Epub 2002 Aug 27.

479. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Crist DM, Peake GT, Stackpole PJ. Clin Exp Pharmacol Physiol 13(7) Jul (1986):513-8.

480. Influence of nandrolonedecanoate on the pituitary-gonadal axis in males. Bijlsma J,Duursma S,Thijssen J,Huber O.Acta Endocrinol 101 (1982):108- 12.

481. Biosynthesis of Estrogens, Gual C, Morato T, Hayano M, Gut M and Dorfman R. Endocrinology 71 (1962):920-25.

482. Aromatization of androstenedione and 19-nortestosterone in human placental, liver and adipose tissues (abstract). Nippon Naibunpi Gakkai Zasshi 62:18-25,1986.

483. Competitive progesterone antagonists: receptor binding and biologic activity of testosterone and 19-nortestosterone derivatives. Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Fertil Steril 1979 May;31(5):552-61.

484. Studies of the biological activity of certain 19-nor steroids in female animals. Pincus G, Chang M, Zarrow M, Hafez E, Merrill A. December 1956.

485. Different Pattern of Metabolism Determine the Relative Anabolic Activity of 19-Norandrogens. J Steroid Biochem Mol Bio 53:255-7,1995. 486.Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha reduced derivatives to the androgen receptor and to other androgen-bidning proteins: A suggested role of 5alpha-reductive steroid metabolism in the dissociation of “myotropic” and “androgenic” activities of 19- nortestosterone.Toth M, Zakar T. J Steroid Biochem 17 (1982):653-60.

487. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1214-22. Epub 2002 Aug 27.

488. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Crist DM, Peake GT, Stackpole PJ. Clin Exp Pharmacol Physiol 1986 Jul;13(7):513-8.

489. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. Karl E. Friedl et al. J Clin Endocrinol Metab 68: 971, 1989.

490. Influence of nandrolonedecanoate on the pituitary-gonadal axis in males. Bijlsma J.,Duursma S,Thijssen J,Huber O.Acta Endocrinol 101 (1982):108- 12.

491. Biosynthesis of Estrogens, Gual C, Morato T, Hayano M, Gut M and Dorfman R. Endocrinology 71 (1962):920-25.

492. Aromatization of androstenedione and 19-nortestosterone in human placental, liver and adipose tissues (abstract). Nippon Naibunpi Gakkai Zasshi 62:18-25,1986.

493. Competitive progesterone antagonists: receptor binding and biologic activity of testosterone and 19-nortestosterone derivatives. Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Fertil Steril 1979 May;31(5):552-61.

494. Studies of the biological activity of certain 19-nor steroids in female animals. Pincus G, Chang M, Zarrow M, Hafez E, Merrill A. December 1956.

495. Different Pattern of Metabolism Determine the Relative Anabolic Activity of 19-Norandrogens. J Steroid Biochem Mol Bio 53:255-7,1995.

496. Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha reduced derivatives to the androgen receptor and to other androgen-bidning proteins: A suggested role of 5alpha-reductive steroid metabolism in the dissociation of “myotropic” and “androgenic” activities of 19- nortestosterone.Toth M, Zakar T. J Steroid Biochem 17 (1982):653-60.

497. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1214-22. Epub 2002 Aug 27.

498. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Crist DM, Peake GT, Stackpole PJ. Clin Exp Pharmacol Physiol 1986 Jul;13(7):513-8.

499. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. Karl E. Friedl et al. J Clin Endocrinol Metab 68: 971, 1989.

500. Influence of nandrolonedecanoate on the pituitary-gonadal axis in males. Bijlsma J,Duursma S,Thijssen J, Huber O.Acta Endocrinol 101 (1982):108- 12.

501. Biosynthesis of Estrogens, Gual C, Morato T, Hayano M, Gut M, and Dorfman R. Endocrinology 71 (1962):920-25.

502. Metabolism of boldenone in man: gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates. Schanzer, Donike. Bol Mass Spec. 21 (1992):3-16.

503. J. Mathieu, Proc. Intern. Symp. Drug Res. 1967, p 134. Chem. Inst. Can., Montreal, Canada.

504. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.

505. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. Bauer, Meyer et al. Acta Pathol Microbiol Imunol Scand Suppl 108 (2000):838-46.

506. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.

507. Disposition of 17 beta-trenbolone in humans. Spranger, Metzler. J Chromatogr 564 (1991):485-92.

508. Cholestasis induced by Parabolan successfully treated with the molecular adsorbent recirculating system. Anand JS et al. ASAIO 2006. JanFeb;52(1):117-8.

509. Herr, M E, Hogg J A, Levin R H, J Am Chem Soc. 78, 500 (1956).

510. Lyster S C, Lund G H, and Stafford R O, Endocrinology 58, 781 (1956).

511. Testing for fluoxymesterone (Halotestin®) administration to man: Identification of urinary metabolites by gas chromatography-mass spectrometry. Kammerer R, Mardink J, Jangels M et al. J Steroid Biochem 36 (1990):659-66.

512. Eisenberg, E. Modern Trends in Endocrinology (H. Gardiner-Hill, ed) p 46. Hoeber, NY (1961)

513. Methyltestosterone, related steroids, and liver function. deLorimier A,Gilbert G. et al. Arch Intern Med v116 (1965):289-94.

514. The effects of fluoxymesterone administration on testicular function. Jones TM, Fang VS et al. J Clin Endocrinol Metab 1977 Jan;44(1):121-9.

515. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science CEnsultants, Natick, MA 1982.

516. Biosynthesis of Estrogens, Gual C, Morato T, Hayano M, Gut M and Dorfman R. Endocrinology 71 (1962):920-25.

517. Aromatization of androstenedione and 19-nortestosterone in human placental, liver and adipose tissues (abstract). Nippon Naibunpi Gakkai Zasshi 62:18-25,1986.

518. Competitive progesterone antagonists: receptor binding and biologic activity of testosterone and 19-nortestosterone derivatives. Reel JR, Humphrey RR, Shih YH, Windsor BL, Sakowski R, Creger PL, Edgren RA. Fertil Steril 1979 May;31(5):552-61.

519. Studies of the biological activity of certain 19-nor steroids in female animals. Pincus G, Chang M, Zarrow M, Hafez E, Merrill A. December 1956.

520. Different pattern of metabolism determine the relative anabolic activity of 19-norandrogens. J Steroid Biochem Mol Bio 53:255-7,1995.

521. Relative binding affinities of testosterone, 19-nortestosterone and their 5-alpha reduced derivatives to the androgen receptor and to other androgen-binding proteins: A suggested role of 5alpha-reductive steroid metabolism in the dissociation of “myotropic” and “androgenic” activities of 19- nortestosterone.Toth M, Zakar T. J Steroid Biochem 17 (1982):653-60.

522. Metabolic effects of nandrolone decanoate and resistance training in men with HIV. Sattler FR, Schroeder ET, Dube MP, Jaque SV, Martinez C, Blanche PJ, Azen S, Krauss RM. Am J Physiol Endocrinol Metab. 2002 Dec;283(6):E1214-22. Epub 2002 Aug 27.

523. Lipemic and lipoproteinemic effects of natural and synthetic androgens in humans. Crist DM, Peake GT, Stackpole PJ. Clin Exp Pharmacol Physiol 1986 Jul;13(7):513-8.

524. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. Karl E. Friedl et al. J Clin Endocrinol Metab 68: 971, 1989.

525. Influence of nandrolonedecanoate on the pituitary-gonadal axis in males. Bijlsma J,Duursma S,Thijssen J, Huber O.Acta Endocrinol 101 (1982):108- 12.

526. 2-Methyl and 2-hydroxymethylene-androstane derivatives. Ringold HJ et al. J Am Chem Soc 1959;81:427-32.

527. Ringold H. J. et al. J. org Chem. 21 (1956):1432.

528. Herstellung des 17-metyl-testosterons und anderer Androsten- und Androstanderivate. Ruzicka L, Goldberg MW. Et al. Helv Chim Acta 18 (1935):1487-98.

529. Effect of anabolic steroids on liver function tests and creatine excretion. Marquardt G. H. et al. JAMA 175 (Mar 11, 1961):851-3.

530. Methyltestosterone, related steroids, and liver function. deLorimier A, Gilbert G. et al. Arch Intern Med v116 (1965):289-94.

531. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl KE, Hannan CJ Jr, Jones RE, Plymate SR. Metabolism. 1990 Jan;39(1):69-74.

532. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

533. Rucicka L et al. Helv Chim. Acta 18 (1935) 1487

534. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982

535. Liver toxicity of a new anabolic agent: methyltrienolone (17-alpha-methyl-4,9,11-estratriene-17 beta-ol-3-one). Kruskemper, Noell. Steroids. 1966 Jul;8(1):13-24.

536. T. Feyel-Cabanes, Compt. Rend. Soc. Biol. 157, 1428 (1963)

537. Protein anabolism produced in man by a new steroid: methyltrienolone. Tremolieres J, Pequignot E. Presse Med. 1965 Nov 6;73(47):2655-8.

538. Specific binding of [3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH). Asselin J, Melancon R, Gourdeau Y, Labrie F, Bonne C, Raynaud JP. J Steroid Biochem. 1979 May;10(5):483-6

539. Liver toxicity of a new anabolic agent: methyltrienolone (17-alpha-methyl-4,9,11-estratriene-17 beta-ol-3-one). Kruskemper, Noell. Steroids. 1966 Jul;8(1):13-24.

540. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982

541. M. Shimizu, G. Ohta et al. Chem. & Pharm. Bull. (Tokyo) 13,895 (1965)

542. Pharmacological studies on experimental nephritic rats. (4) Improvement of hyperlipemic models in rats utilizing anti-rat kidney rabbit serum and effects of anti-hyperlipemic agents on serum lipid levels. Suzuki Y, Honda Y, Ito M. Jpn J Pharmacol. 1978 Oct;28(5):729-38.

543. The use of oxandrolone in hyperlipidaemia. Doyle AE, Pinkus NB, Green J. Med J Aust. 1974 Feb 2;1(5):127-9.

544. Clinical evaluation of a new anabolic agent 7a,17a-dimethyltestosterone (bolasterone). Korst, D. R., Bowers, C. Y., Flokstra, J. H., McMahon, F.G. Clin. Pharmacol. Therap. 4:734-9 (1963).

545. The synthesis of some 7alpha and 7beta methyl steroid hormones. Campbell JA, Babcock JC. J Am Chem Soc 81:4069-74 (1959).

546. Anabolic and androgenic activities of 7a,17a-dimethyltestosterone (U-19,763), a new anabolic steroid. Stucki J. C., Duncan G. W., Lyster S.C.

547. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

548. NEBIDO Prescribing Information (2004). Schering AG Germany.

549. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F 1976 Clin Pharmacol Ther 20:233-237.

550. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Karl Friedl, Charles Hannan et al. Metabolism 39(1) 1990:69-74.

551. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

552. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Atam Singh, Stanley Hsia, et al. J Clin Endocrinol Metab 87: 136-43, 2002.

553. Colton F.B., Nysted L.N., Riegel B., et al. J Am Chem Soc. 79 (1954), 1123.

554. Studies of the biological activity of certain 19-nor steroids in female animals. Pincus G., Chang M., Zarrow M., Hafez E., Merrill A. December 1956.

555. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

556. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F 1976 Clin Pharmacol Ther 20:233-237.

557. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Karl Friedl, Charles Hannan et al. Metabolism 39(1) 1990:69-74.

558. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

559. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Atam Singh, Stanley Hsia, et al. J Clin Endocrinol Metab 87: 136-43, 2002.

560. Metabolism of anabolic steroid drugs in man and the marmoset monkey (callithrix jacchus)-I. Nilevar and Orabolin. Ward R, Lawson A.M, Shackleton C.L.H. J Steroid Biochem 8 (1977):1057-63.

561. De Winter, M. S. et al. Chem. and Ind. (London) 1959, 905.

562. Overbeek G.A. et al. Acta Endicrin. (Kbh) 40 (1962):133.

563. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

564. Doerner G and Schubert A. Proc. Intern. Congr. Hormonal Steroids, Milan 1962, Excerpta Med. Intern. Congr. Ser. No. 51, 210.

565. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

566. Miescher, Wettstein & Tschopp (1936) Schweiz. Med. Wschr. 66, 310.

567. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F 1976 Clin Pharmacol Ther 20:233-237.

568. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) 1990: 69-74.

569. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

570. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Atam Singh, Stanley Hsia, et al. J Clin Endocrinol Metab 87: 136-43, 2002.

571. J. Mathieu, Proc. Intern. Symp. Drug Res. 1967, p 134. Chem. Inst. Can., Montreal, Canada.

572. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.

573. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. Bauer, Meyer et al. Acta Pathol Microbiol Imunol Scand Suppl 108 (2000):838-46.

574. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.

575. Disposition of 17 beta-trenbolone in humans. Spranger, Metzler. J Chromatogr 564 (1991):485-92.

576. Cholestasis induced by Parabolan successfully treated with the molecular adsorbent recirculating system. Anand JS et al. ASAIO 2006. JanFeb;52(1):117-8.

577. Wiechert R. et al. Chem Ber. 93 (1960):1710.

578. Methenolone acetate, Summary of information for clinical investigators, New Brunswick, NJ.The Squibb Institute for Medical Research, May 30, 1962.

579. Anabolic effects of methenolone enanthate and methenolone acetate in underweight premature infants and children. New York State Journal of Medicine March 1, 1965, 645-8.

580. Kruskemper H L et al, Exc Medica (Amsterd.) Congr. Ser. No. 51 (1962), 209.

581. Weller O.Arzneimittelforsch.12 (1962):234.

582. Proc. Intern. Congr. Hormonal Steroids, Milan, 1962. Excerpta Med. Intern. Congr. Ser No. 51, p. 209. Excerpta. Med. Found., Amsterdam, 1962.

583. Failure of non-17-alkylated anabolic steroids to produce abnormal liver function tests. J Clin Endocrinol Metab. 1964 Dec;24:1334-6.

584. Fatal outcome of a patient with severe aplastic anemia after treatment with metenolone acetate. Ann Hematol. 1993 Jul;67(1):41-3. Tsukamoto N, Uchiyama T, Takeuchi T, Sato S, Naruse T, Nakazato Y.

585. Comparative studies about the influence of metenoloneacetate and mesterolone on hypophysis and male gonads. Trenkner R, Senge T, Hienz H et al.Arzneimittelforschung. 1970 20(4):545-7.

586. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

567. Wiechert R.et al.Chem Ber. 93 (1960):1710.

568. Methenolone enanthate, Summary of information for clinical investigators, New Brunswick, NJ. The Squibb Institute for Medical Research, April 15, 1962.

569. Anabolic effects of methenolone enanthate and methenolone acetate in underweight premature infants and children. New York State Journal of Medicine March 1, 1965, 645-8.

570. Proc. Intern. Congr. Hormonal Steroids, Milan, 1962. Excerpta Med. Intern. Congr. Ser No. 51, p. 209. Excerpta. Med. Found., Amsterdam, 1962.

571. Failure of non-17-alkylated anabolic steroids to produce abnormal liver function tests. J Clin Endocrinol Metab. 1964 Dec;24:1334-6.

572. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Saartok T, Dahlberg E, Gustafsson JA. Endocrinology. 1984 Jun;114(6):2100-6.

573. Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Jockenhovel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Muller-Wieland D, Krone W. Metabolism. 1999 May;48(5):590-6.

574. Comparative studies about the influence of metenolonacetate and mesterolone on hypophysis and male gonads. Trenkner R, Senge T, Hienz A, et al. Arzneim-Forsch. (Drug Res) Jahrgang 30, Nr. 4 (1970):545-7.

575. The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study). Itil TM, Michael ST, Shapiro DM, Itil KZ. Methods Find Exp Clin Pharmacol. 1984 Jun;6(6):331-7.

576. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F 1976 Clin Pharmacol Ther 20:233-237.

577. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Karl Friedl, Charles Hannan et al. Metabolism 39(1) 1990:69-74.

578. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

579. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab 87:136-43, 2002.

580. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

581. Testosterone replacement, cardiovascular system and risk factors in the aging male. Vigna GB, Bergami E. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):69-74.

582. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

583. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Karl Friedl, Charles Hannan et al. Metabolism 39(1) 1990: 69-74.

584. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

585. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab 87: 136-43, 2002.

586. Product Data Sheet: Sustanon 250. August 31, 2001. Pharmaco (N.Z.) LTD Auckland New Zealand.

587. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

588. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) 1990: 69-74.

589. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

590. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab 87: 136-43, 2002.

591. History of diethylstilbestrol use in cattle.A. P. Raun and R. L. Preston. 2002, American Society of Animal Science.

592. Long-term experience with testosterone replacement through scrotal skin. In Nieschlag E and Behre HM (eds) Testosterone. Action, Deficiency, Substitution. Atkinson LE, Chang Y-L and Snyder PJ (1998) Springer, Berlin, Germany 365–

388.

593. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

594. Testosterone replacement, cardiovascular system and risk factors in the aging male. Vigna GB, Bergami E. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):69-74.

595. New androgen for retarded action; testosterone phenylpropionate. Klotz HP, Avril Y. Therapie. 1955;10(4):588-90.

596. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

597. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) 1990:69-74

598. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

599. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab 87: 136-43, 2002.

600. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

601. Testosterone replacement, cardiovascular system and risk factors in the aging male. Vigna GB, Bergami E. J Endocrinol Invest. 2005;28(11 Suppl Proceedings):69-74.

602. The effects of depot testosterone therapy on serum levels of luteinizing hormone and follicle-stimulating hormone in patients with Klinedelter’s syndrome and hypogonadotrophic eunuchoidism. Fukutani K, Isurugi K et al. J Clin Endocrinol Metab 39:856-64.

603. Enzyme induction by oral testosterone. Johnsen SG, Kampmann JP, Bennet EP, Jorgensen F. 1976 Clin Pharmacol Ther 20:233-237.

604. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Friedl K, Hannan C et al. Metabolism 39(1) 1990:69-74

605. Testosterone dose-response relationships in healthy young men. Bhasin S, Woodhouse L et al. Am J Physiol Endocrinol Metab 281: E1172-81, 2001.

606. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. Singh A, Hsia S, et al. J Clin Endocrinol Metab 87: 136-43, 2002.

607. J. Mathieu, Proc. Intern. Symp. Drug Res. 1967, p 134. Chem. Inst. Can., Montreal, Canada.

608. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.

609. Characterisation of the affinity of different anabolics and synthetic hormones to the human androgen receptor, human sex hormone binding globulin and to the bovine progestin receptor. Bauer, Meyer et al. Acta Pathol Microbiol Imunol Scand Suppl 108 (2000):838-46.

610. Unique steroid congeners for receptor studies. Ojasoo, Raynaud. Cancer Research 38 (1978):4186-98.

611. Disposition of 17 beta-trenbolone in humans. Spranger, Metzler. J Chromatogr 564 (1991):485-92.

612. Cholestasis induced by Parabolan successfully treated with the molecular adsorbent recirculating system. Anand JS et al. ASAIO 2006. JanFeb;52(1):117-8.

613. Clinton R. O. et al. J. Amer chem. Soc. 81 (1959):1513.

614. U.S.Patent # 3,030,358.

615. Anabolic-androgenic steroid interaction with rat androgen receptor in vivo and in vitro: a comparative study. Feldkoren BI, Andersson S. J Steroid Biochem Mol Biol. 2005 Apr;94(5):481-7. Epub 2005 Mar 17.

616. The differential effects of stanozolol on human skin and synovial fibroblasts in vitro: DNA synthesis and receptor binding. Ellis AJ, Cawston TE, Mackie EJ. Agents Actions. 1994 Mar;41(1-2):37-43.

617. Identification of a specific binding site for the anabolic steroid stanozolol in male rate liver microsomes. Boada LD, Fernandez L et al. J Pharmacol Exp Ther 1996 Dec;279(3):1123-9.

618. Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes. Fernandez L, Chirino R, Boada LD, Navarro D, Cabrera N, del Rio I, Diaz-Chico BN. Endocrinology. 1994 Mar;134(3):1401-8.

619. Desaulles P.A.et al.Helv. Med Acta 27 (1960),

479.

620. Sex hormone-binding globulin response to the anabolic steroid stanozolol: Evidence for its suitability as a Biological androgen sensitivity test. G Sinnecker, S Kohler. Journal of Clin Endo Metab. 68: 1195,1989.

621. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Ivone Martins Ferreira, Ieda Verreschi et al. CHEST 114 (1) July 1998 19-28.

622. Androgenic/Anabolic steroid-induced toxic hepatitis. Stimac D, Milic S, Dintinjana RD, Kovac D, Ristic S. J Clin Gastroenterol. 2002 Oct;35(4):350-2.

623. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, Herbert PN. JAMA. 1989 Feb 24;261(8):1165-8.

624. The effect of intramuscular stanozolol on fibrinolysis and blood lipids. Small M, McArdle BM, Lowe GD, Forbes CD, Prentice CR. Thromb Res. 1982 Oct 1;28(1):27-36.

625. Alteration of hormone levels in normal males given the anabolic steroid stanozolol. Small M, Beastall GH, Semple CG, Cowan RA, Forbes CD. Clin Endocrinol (Oxf).1984 Jul;21(1):49-55.

626. Anabolic Steroids and Sports Volume II. James E. Wright. Sports Science Consultants, Natick, MA 1982.

627. The effect of stanozolol on nitrogen retention in the dog. Olson ME, Morck DW, Quinn KB. Can J Vet Res. 2000 Oct;64(4):246-8.

628. Protein synthesis in isolated forelimb muscles. The possible role of metabolites of arachidonic acid in the response to intermittent stretching. Smith, Palmer et al. Biochem J. 1983 214,153-61.

629. The influence of changes in tension on protein synthesis and prostaglandin release in isolated rabbit muscles. Palemr, Reeds et al. Biochem J. 1983 214,1011-14.

630. Protein synthesis and degradation in isolated muscle. Effect of n3 and n6 fatty acids. Palmer, Wahle. Biochem J. 1987 242, 615-18.

631. Regular exercise modulates muscle membrane phospholipid profile in rats. Helge et al. J. Nutr. 1999 129:1636-42.

632. Exercise training reduces skeletal muscle membrane arachidonate in obese (fa/fa) Zucker rat. Ayre et al. J. Appl. Physiol. 1998 85(5):1898-1902.

633. Effects of physical exercise on phospholipid fatty acid composition in skeletal muscle. Andersson et al. Am. J. Physiol. 274 (Endocrinol. Metab. 37):E432-38 1998.

634. Effects of an omnivorous diet compared with a lactoovovegetarian diet on resistance-training –induced changes in body composition and skeletal muscle in older men. W Campbell, M Barton et al. Am J Clin Nutr 70(1999):1032-9.

635. The effect of dietary arachidonic acid on plasma lipoprotein distribution, apoproteins, blood lipid levels, and tissue fatty acid composition in humans. G.J. Nelson, P.C. Schmidt et al. Lipids 32: 427-33 (1997).

636. The effect of dietary arachidonic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Nelson CJ, Schmidt PC et al. Lipids 32(4):421-5 (1997).

637. Effects of dietary arachidonic acid on human immune response. Kelley DS, Taylor PC et al. Lipids 32(4):449-56 (1997).

638. Dietary intake of N-3 and N-6 fatty acids and the risk of prostate cancer. M Leitzmann, M Stampfer et al. Am J Clin Nutr 80:204-16 (2004).

639. Dietary (n-6) PUFA and intestinal tumorigenesis. J Whelan, M McEntee et al. J Nutr 134:3421S-26S (2004).

640. Action of heptaminol hydrochloride on contractile properties in frog isolated twitch muscle fibre. Allard B, Jacquemond V, Lemtiri-Chlieh F, Pourrias B, Rougier O. Br J Pharmacol. 1991 Nov;104(3):714-8.

641. Heptaminol chlorhydrate: new data. Pourrias B. Ann Pharm Fr. 1991;49(3):127-38.

642. On the mode of action of heptaminol (author’s transl)] Grobecker H, Grobecker H. Arzneimittelforschung. 1976;26(12):2167-71.

643. Prostaglandins and the control of muscle protein synthesis and degradation. Prostaglandins Leukot Essent Fatty Acids. 1990 Feb;39(2):95-104

644. Prostaglandin F2(alpha)stimulates growth of skeletal muscle cells via an NFATC2-dependent pathway. Horsley V, Pavlath GK. J Cell Biol. 2003 Apr 14; 161(1):111-8.

645. Stretch-induced prostaglandins and protein turnover in cultural skeletal muscle.Vandenburgh HH, Hatfaludy S, Sohar I, Shansky J. Am J Physiol. 1990 Aug;259(2 Pt 1): C232-40.

646. Skeletal muscle PGF(2)(alpha) and PGE(2) in response to eccentric resistance exercise: influence of ibuprofen acetaminophen. Trappe TA, Fluckey JD, White F, Lambert CP, Evans WJ. J Clin Endocrinol Metab. 2001 Oct;86(10):5067-70.

645. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. J Biol Chem 1998 Jan 23;273(4):1855-8

646. Preclinical pharmacology of “Arimidex” (anastrozole; ZD1033)—a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996 Jul;58(4):439- 45

647. Anastrozole alone or in combimation with tamoxifen versus tamoxifen alone for adjunctive treatment of postmenopausal women with early breast cancer. Frist results of the ATAC randomized trial. Lancet 2002; 359:2131-39

648. History and Advancement of Anastrozole in the Treatment of Breast Cancer. Edited by Aman Buzdar & Michael Baum. RSM Press, February 2003

649. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: Studies on the mechanism of action. Dexter RN, FishmanLM, Ney RC et al. J Clin Endocrinol 27 (1967) 473-80

650. First generation aromatase inhibitors –aminoglutethimide and testololactone. Cocconi G. Breast Cancer Res Treat 1994;30(1):57-80

651. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Graves PE, Salhanick HA. Endocrinol 105 (1979) 52-57

652. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. Lawrence SE, Faught et al. J. Pediatr. 2004 Jul;145(1):71-6

653. Effects of raloxifene on gonadotropins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol. 2004 Apr;150(4):539-46

654. Raloxifene decreases serum IGF-1 in male patients with active acromegaly.Dimaraki EV, Symons KV,Barkan AL. Eur J Endocrinol. 2004 Apr;150(4):481- 7

655. Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment. Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, et al. J Clin Oncol. 2002; 1:57.

656. Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen. Anticancer Res. 2002 JulAug;22(4):2317-9.

657. Fulvestrant. Cheung KL, Robertson JF. Expert Opin Investig Drugs 2002 Feb;11(2):303-308

658. Effects of estrogen on the release of gonadotropins and prolactin in male pseudohermaphrodites. Barbarino A, De Darinis L et al. J endocrinol Invest. 1979 Jan-Mar;2(1):41-4

659. Estrogen-dependent plasma prolactin response to gonadotropin-releasing hormone in intact and castrated men. Barbarino A, De Marinis L. et al. J Clin Endocrinol Metab. 1982 Dec;55(6):1212-6

660. Effects of progesterone administration on follicle-stimulating hormone and prolactin release in estrogen treated eugonadal adult men. Mancini A, De Marinis L. et al. Andrologia 1991 Sep-Oct;23(5):373-9

661. Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary. Tong Y et al. Endocrinology. 1989 Oct;125(4):1821-8

662. Effects of depot testosterone administration on serum levels of testosterone, FSH, LH and prolactin. Ruiz E. et al. J Endocrinol Invest. 1980 OctDec;3(4):385-8.

663. Response of serum hormones to androgen administration in power athletes. Alen M. Reinila M. et al. Med Sci Sports Exerc. 1985 Jun;17(3):354-9.

664. Effect of androgenic anabolic steroids on sperm quality and serum hormone levels in adult male bodybuilders. Torres-Calleja J. et al. Life Sci. 2001 Mar 2;68(15):1769-74.

665. Anabolic steroid-associated hypogonadism in male hemodialysis patients. Maeda Y. et al. Clin Nephrol. 1989 Oct;32(4):198-201.

666. Prescribing Information for Dostinex Tablets. Pharmacia & Upjohn 2003.

667. Enhancement of linear growth and weight gain by cyproheptadine in children with hypopituitarism receiving growth hormone therapy. Kaplowitz PB, Jennings S. Pediatr. 1987 Jan;110(1):140-3.

668. Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. Summerbell CD, Youle M, McDonald V, Catalan J, Gazzard BG. Int J STD AIDS. 1992 Jul-Aug;3(4):278-80.

669. Cyproheptadine no longer promoted as an appetite stimulant. WHO Drug Info 1994; 8:66

670. Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients. Kojuri J,Vosoughi AR, Akrami M. Lipids Health Dis. 2007 Mar 1;6:5.

671. Effects of garlic extract consumption on blood lipid and oxidant/antioxidant parameters in humans with high blood cholesterol. Durak I, Kavutcu M, Aytaç B, Avci A, Devrim E, Ozbek H, Oztürk HS. J Nutr Biochem. 2004 Jun;15(6):373-7. 672.866. 52.

673. Effect of ground green tea drinking for 2 weeks on the susceptibility of plasma and LDL to the oxidation ex vivo in healthy volunteers. Gomikawa S, Ishikawa Y. et al. Kobe J Med Sci. 2008 May 23;54(1):E62-72.

674. Cardiovascular protective effects of resveratrol. Bradamante S, Barenghi L, Villa A. Cardiovasc Drug Rev. 2004 Fall;22(3):169-88.

675. Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. Moruisi KG, Oosthuizen W, Opperman AM. J Am Coll Nutr. 2006 Feb;25(1):41-8. Review.

676. Role of policosanols in the prevention and treatment of cardiovascular disease.Varady KA,Wang Y, Jones PJ. Nutr Rev. 2003 Nov;61(11):376-83. Review.

677. Role of selenium in cytoprotection against cholesterol oxide-induced vascular damage in rats. Huang K, Liu H, Chen Z, Xu H. Atherosclerosis. 2002 May;162(1):137-44.

678. Inositol hexaniacinate. Altern Med Rev. 1998 Jun;3(3):222-3.

679. Pownall JH et al , Atherosclerosis. 1999; 143:285-297

680. Harris WS et al, J Cardio Risk 1997; 4:385-391

681. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Bays H. Am J Cardiol. 2006 Aug 21;98(4A):71i-76i. Epub 2006 May 30.

682. Gissi P Study, The Lancet 1999; Vol 354:447-55

683. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. Park Y, Harris WS. J Lipid Res. 2003 Mar;44(3):455-63. Epub 2002 Dec 1.

684. The hypotriglyceridemic effect of eicosapentaenoic acid in rats is reflected in increased mitochondrial fatty acid oxidation followed by diminished lipogenesis. Willumsen N, Skorve J, Hexeberg S, Rustan AC, Berge RK. Lipids. 1993 Aug;28(8):683-90.

685. Docosahexaenoic acid (DHA) and hepatic gene transcription. Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B. Chem Phys Lipids. 2008 May;153(1):3-13. Epub 2008 Feb 23.

686. Why do omega-3 fatty acids lower serum triglycerides? Harris WS, Bulchandani D. Curr Opin Lipidol. 2006 Aug;17(4):387-93.

687. Effects of modafinil ingestion on exercise time to exhaustion. Jacobs I, Bell DG. Med Sci Sports Exerc. 2004 Jun;36(6):1078-82.

688. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH.Arch Intern Med. 1984 Jun;144(6):1143-8

689. Modalities of the food intake-reducing effect of sibutramine in humans. Chapelot D, Marmonier C, Thomas F, Hanotin C. Physiol Behav. 2000 Jan;68(3):299-308.

690. Thermogenic effects of sibutramine and its metabolites. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ. Br J Pharmacol. 1999 Mar;126(6):1487-95.

691. A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects. Zhao Y, Wang X, Yan Z. Zhonghua Yu Fang Yi Xue Za Zhi. 2001 Sep;35(5):329-32.

692. Effects of ketotifen and clenbuterol on beta-adrenergic receptor functions of lymphocytes and on plasma TXB-2 levels of asthmatic patients. Huszar E, Herjavecz I et al. Z Erkr Atmungsorgane 1990;175(3):141-6

693. Effect of prednisolone and ketotifen on beta 2-adrenoceptors in asthmatic patients receiving beta 2-bronchodilators. Brodde OE, Howe U et al. Eur J Clin Pharmacol 1988;34(2):145-50 Ketotifen alone or as an additional medication for the long-term control of asthma and wheeze in children. Bassler D, et al. The Cochrane Database of Systematic Reviews; Issue 1. Chichester: John Wiley; 2004.

695. The emergence of endocrinology. Welbourn RB. Gesnerus. 1992;49 Pt 2:137-50.

696. Why do we continue to write for Synthroid? Volume XI, Issue 8 Harold J. DeMonaco, M.S., Director of Drug Therapy Management. A publication of the Drug Therapy Committee, Massachusetts General Hospital and the MAssachusets General Physicians Organization.

697. Bioequivalence of generic and brand-name levothyroxine products in the treatment of hypothyroidism. Dong BJ. Hauck WW. Gambertoglio JG. Gee L. White JR. Bubp JL. Greenspan FS. JAMA. 1997; 277: 1205-1213.

698. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Rotunda AM, Suzuki H et al. Dermatol Surg. 2004 Jul;30(7):1001-8

699. Phosphatidylcholine increases the secretion of triacylglycerol-rich lipoproteins by CaCo-2 cells. Mathur SN, Born E et al. Biochem J. 1996 Mar 1;314 (pt 2):569-75

700. Lipolysis injection with phosphatidylcholine (Lipostabil N) examination of blood values after subcutaneous administration. Dr. Franz Hasengschwandtner. Online Article.

701. Clinical experience and safety using phosphatidylcholine injections for the localized reduction of subcutaneous fat: a multicentre, retrospective UK study. Journal of Cosmetic Dermatology. 5(3):218-226, September 2006. Palmer, Mark MD; Curran, John MD; Bowler, Patrick MD

702. Stimulation of growth hormone secretion with human growth hormone releasing factors (GRF1-44, GRF1-40, GRF1-29) in normal subjects. Losa M, Schopohl J, Müller OA, von Werder K. Klin Wochenschr. 1984 Dec 3;62(23):1140-3.

703. Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency. Ranke MB, Gruhler M, Rosskamp R, Brügmann G, Attanasio A, Blum WF, Bierich JR. Eur J Pediatr. 1986 Dec;145(6):485-92.

704. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. J Clin Endocrinol Metab. 1996 Mar;81(3):1189-96.

705. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Barron JL, Coy DH, Millar RP. Peptides. 1985 May-Jun;6(3):575-7.

706. A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Chen RG, Shen YN, Yei J, Wang CF, Xie DH, Wang XH, Zhou JD, Chen CY, Wu YL, Gunnarsson R, et al. Acta Paediatr Suppl. 1993 Mar;388:32-5; discussion 36.

707. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. Prakash A, Goa KL. BioDrugs. 1999 Aug;12(2):139-57.

708. Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing children. Brain CE, Hindmarsh PC, Brook CG. Clin Endocrinol (Oxf ). 1990 Feb;32(2):153-63.

709. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. Thorner M, Rochiccioli P, Colle M, Lanes R. et al. J Clin Endocrinol Metab. 1996 Mar;81(3):1189-96.

710. Growth hormone (GH) profiles in response to continuous subcutaneous infusion of GH-releasing hormone(1-29)-NH2 in children with GH deficiency. Tauber MT, Pienkowski C, Pigeon P, Cataldi M, Rochiccioli P. Acta Paediatr Suppl. 1993 Mar;388:28-30; discussion 31.

711. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Neyzi O, Yordam N et al. Acta Paediatr Suppl. 1993 Mar;388:16-21; discussion 22.

712. Growth Hormone–Releasing Hormone in HIV-Infected Men With Lipodystrophy A Randomized Controlled Trial. Polyxeni Koutkia; Bridget Canavan; Jeff Breu; et al. JAMA, July 14, 2004—Vol 292, No. 2.

713. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Berelowitz M, Szabo M, Frohman LA, Firestone S, Chu L, Hintz RL. Science. 1981 Jun 12;212(4500):1279-81.

714. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Walker RF. Clin Interv Aging. 2006;1(4):307-8.

715. EMD Serono, Inc. to Discontinue Geref Diagnostic 8/5/2008

716. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Vittone J, Blackman MR, BusbyWhitehead J. et al. Metabolism. 1997 Jan;46(1):89-96.

717. Section. 303(e)(1)/FDCA, 21 U.S.C. 333(e)(1)

718. Treatment of pituitary dwarf with human growth hormone. Raben MS. J Clin Endocrinol Metab 18:901-903 1958.

719. Long term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediat 144:430-

436.

720. Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height. J Pediat 131:55-57.

721. Production of Authentic Recombinant Somatropin. Linda Fryklund. Acta Paediatrica Volume 76 Issue s331 Page 5-8, January 1987.

722. Five-year follow-up of growth hormone antibodies in growth hormone deficient children treated with recombinant human growth hormone. G Massa et al. Clin Endocrinol 38(2) 137-42 (Feb 1993).

723. Identification of an insulin-responsive element in the promoter of the human gene for insulin-like growth factor binding protein-1. J Biol Chem 268:17063-68,1995

724. Evidence supporting a direct suppressive effect of growth hormone on serum IGFBP-1 levels. Experimental studies in normal, obese and GH-deficient adults.Growth Hormone and IGF Research 9:52-60,1999

725. Growth hormone induced increase in serum IGFBP-3 level is reversed by anabolic steroids in substance abusing power athletes. Clin Endocrinol (Oxf ) 49:459-63,1998

726. United Kingdom multicentre clinical trial of somatrem. Milner RD, Barnes ND, Buckler JM, Carson DJ, Hadden DR, Hughes IA, Johnston DI, Parkin JM,

727. Antigenicity and efficacy of authentic sequence recombinant human growth hormone (somatropin): first-year experience in the United Kingdom. Buzi F, Buchanan CR, Morrell DJ, Preece MA. Clin Endocrinol (Oxf ) 1989 May;30(5):531-8

728. Pioneering recombinant growth hormone manufacturing: pounds produced per mile of height. J Pediat 131:55-57.

729. Metformin:its botanical background. CJ Bailey, C Day. Pract Diab Int April 2004 Vol. 21 No. 3

730. Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (N.N.D.G.). Sterne J. Maroc Med 1957; 36: 1295-96.

731. Glucophage, Glucophage XR Prescribing Information. Revision January 2009. Brystol-Myers Squibb Company.

732. Protein anabolic actions in the human body. W.M. Bennet et al. Diabetic Medicine 1991, 8 199-207

733. Effect of physiologic hyperinsulinemia on skeletal muscle protein synthesis and breakdown in man. R Gelfand et al. J Clin Invest. 80, July 1987 1-6

734. Insulin action on muscle protein kinetics and amino acid transport during recovery after resistance exercise. G Biolo, B Williams et al. Diabetes Vol 48, May 1999 949-957.

735. Insulin signaling and insulin sensitivity after exercise in human skeletal muscle. Jorgen F. P. Wojtaszewski et al. Diabetes Vol 49, March 2000 325-31

736. Intramuscular injection of insulin lispro or soluble human insulin: pharmacokinetics and glucodynamics in Type 2 diabetes. Z. Milicevic et al. Diabetes UK. Diabetic Medicine, 18 562-566

737. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Walker AF, Marakis G, Simpson E, Hope JL, Robinson PA, Hassanein M, Simpson HC. Br J Gen Pract. 2006 Jun;56(527):437-43.

738. Antihypertensive effects of the flavonoid quercetin. Perez-Vizcaino F, Duarte J, Jimenez R, Santos-Buelga C, Osuna A. Pharmacol Rep. 2009 JanFeb;61(1):67-75.

739. Effects of nattokinase on blood pressure: a randomized, controlled trial. Kim JY, Gum SN et al. Hypertens Res. 2008 Aug;31(8):1583-8.

740. Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis. Reinhart KM, Coleman CI, Teevan C, Vachhani P, White CM. Ann Pharmacother. 2008 Dec;42(12):1766-71. Epub 2008 Nov 18.

741. Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Antonello M, Montemurro D, Bolognesi M, Di Pascoli M, Piva A, Grego F, Sticchi D, Giuliani L, Garbisa S, Rossi GP. Am J Hypertens. 2007 Dec;20(12):1321-8.

742. Effect of Ginkgo biloba on blood pressure and incidence of hypertension in elderly men and women. Brinkley TE, Lovato JF, Arnold AM, Furberg CD, Kuller LH, Burke GL, Nahin RL, Lopez OL, Yasar S, Williamson JD; Ginkgo Evaluation of Memory (GEM) Study Investigators. Am J Hypertens. 2010 May;23(5):528-33. Epub 2010 Feb 18.

743. Blood pressure lowering effect of an olive leaf extract (Olea europaea) in L-NAME induced hypertension in rats. Khayyal MT, el-Ghazaly MA, Abdallah DM, Nassar NN, Okpanyi SN, Kreuter MH. Arzneimittelforschung. 2002;52(11):797-802.

744. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Kumar A, Kaur H, Devi P, Mohan V. Pharmacol Ther. 2009 Dec;124(3):259-68. Epub 2009 Jul 25.

745. The role of endogenous GHRH in arginine-, insulin-, clonidine- and l-dopa-induced GH release in normal subjects. Hanew K, Utsumi A. Eur J Endocrinol. 2002 Feb;146(2):197-202.

746. Effect of chronic clonidine administration on GH secretion in adult human subjects. Catania A, Baldini M et al. Exp Clin Endocrinol. 1991 Mar;97(1):76-80.

747. Effect of chronic clonidine treatment on urinary growth hormone excretion and linear growth in children with short stature. Sanmartí A, Lucas A, Granada ML, Salinas I, Reverter JL, Cuatrecasas JM, Foz M, Audi L. Horm Res. 1990;34(5-6):193-6.

748. A new antihypertensive drug: clonidine or Catapressan. Amery A, Bossaert H, Deruyttere M, Verstreken G. Acta Clin Belg. 1969;24(6):334-55.

749. Medicine and Drugs: Clonidine. Medicinenet.com/clonidine/article.htm. Omudhome Ogbru, Jay W. Marks, MD.

750. Multivitamins and phospholipids complex protects the hepatic cells from androgenic-anabolic-steroids-induced toxicity. Pagonis TA, Koukoulis GN, Hadjichristodoulou CS, Toli PN, Angelopoulos NV. Clinical Toxicol (2008) 46, 57-66.

751. Hepatoprotective effects of Liv-52 on ethanol induced liver damage in rats. Indian J Exp Biol. 1999 Aug;37(8):762-6.

752. The effect of the heptoprotective agent LIV 52 on liver damage. Cas Lek Cesk. 1997 Dec 17;136(24):758-60.

753. Hepatoprotective effect of Liv-52 and kumaryasava on carbon tetrachloride induced hepatic damage in rats. Indian J Exp Biol. 1997 Jun;35(6):655-7.

754. Role of Liv-52 in protection against beryllium intoxication. Biol Trace Elem Res. 1994 Jun;41(3):201-15.

755. Alcohol hangover and Liv.52. Chauhan BL, Kulkarni RD. Eur J Clin Pharmacol. 1991;40(2):187-8.

756. Hepatoprotective effects of Liv-52 on ethanol induced liver damage in rats. Sandhir R, Gill KD. Indian J Exp Biol. 1999 Aug;37(8):762-6.

757. Himalaya’s Liv.52/LiverCare Approved as a Herbal Drug in Switzerland. Houstan (BW HealthWire) April 4, 2002.

758. Anti-hepatotoxic effects of root and root callus extracts of Cichorium intybus L. Zafar R, Mujahid Ali S. J Ethnopharmacol. 1998 Dec;63(3):227-31.

759. Aqueous extract of Terminalia arjuna prevents carbon tetrachloride induced hepatic and renal disorders. Manna P, Sinha M, Sil PC. BMC Complement Altern Med. 2006 Sep 30;6:33.

760. Achillea millefolium L. s.l. revisited: recent findings confirm the traditional use. Benedek B, Kopp B. Wien Med Wochenschr. 2007;157(13-14):312-4.

761. N-acetyl-cysteine protects liver from apoptotic death in an animal model of fulminant hepatic failure. San-Miguel B, Alvarez M, Culebras JM, GonzálezGallego J, Tuñón MJ. Apoptosis. 2006 Nov;11(11):1945-57.

762. Toxic effects of anabolic-androgenic steroids in primary rat hepatic cell cultures.Welder AA, Robertson JW, Melchert RB. J Pharmacol Toxicol Methods. 1995 Aug;33(4):187-95.

763. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Saller R, Brignoli R, Melzer J, Meier R. Forsch Komplementmed. 2008 Feb;15(1):9-20.

764. A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway. Morimitsu Y, Nakagawa Y et al. J Biol Chem. 2002 Feb 1;277(5):3456-63.Epub 2001 Nov 12.

765. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha reductase inhibitor. Clark RV, Hermann DJ, Cunningham GR et al. J Clin Endocrinol Metab 2004 May;89(5):2179-84

766. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. J Pharmacol Exp Ther. 1997 Sep;282(3):1496-

502.

767. Exogenous stimulation of corpus luteum formation in the rabbit; influence of extracts of human placenta, decidua, fetus, hydatid mole and corpus luteum on the rabbit gonad. Hirose T 1920 J Jpn Gynecol Sot 16:1055.

768. Die Schwangerschaftsdiagnose ausdem Ham durch Nachweis des Hypophysenvorderlappen-hormone. II. Pracktishe und theoretische Ergebnisse aus den hamuntersuchungen. Ascheim S, Zondek B 1928 Klin Wochenschr 7:1453-1457.

769. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysis. Lijesen GKS,et al.Br J Clin Pharmacol 1995; 40: 237–43.

770. A randomized three-way cross-over study in healthy pituitary-suppressed women to compare the bioavailability of human chorionic gonadotrophin (Pregnyl) after intramuscular and subcutaneous administration. Mannaerts BM, Geurts TB, Odink J. Hum Reprod. 1998 Jun;13(6):1461-4.

771. Acute stimulation of aromatization in Leydig cells by human chorionic gonadotropin in vitro. Proc Natl Acad Sci USA 76:4460-3,1979.

772. The different mechanisms for suppression of pituitary and testicular function. Sandow J, Engelbart K, von Rechenberg W.Med Biol. 1986;63(5- 6):192-200.